Multinationals Go Missing In Guangdong Essential Drug Tenders
This article was originally published in PharmAsia News
The widely watched Guangdong province drug tender released its first batch of results for essential drugs. As expected, prices dropped, but the degree to which they were chopped may see multinational companies walk away from EDL tenders altogether.
You may also be interested in...
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.